Bundesverband kostenloser Wochenzeitungen e.V. (BVDA)

BVDA-Tagung 2026: Deutscher Prospekt Award verliehen

Essen / Berlin (ots)

Die Unternehmen Hieber's Frische Center in der Kategorie Regional, Denns BioMarkt (Kategorie Klassik Food) und EURONICS (Kategorie Klassik Non-Food) sind heute Abend in Essen mit dem Deutschen Prospekt Award in Gold ausgezeichnet worden. Der Bundesverband kostenloser Wochenzeitungen (BVDA) würdigte damit vor rund 170 geladenen Gästen vornehmlich gedruckte Werbebeilagen, die sich durch Relevanz, Design, die sinnvolle Verlängerung ins Digitale und Nachhaltigkeit auszeichnen.

Anlässlich der Jahrestagung des Verbands gingen zweite und dritte Plätze an die Unternehmen Engelhorn - "Lifestyle im Quadrat - 135 Jahre Engelhorn" (Silber) und Bäckerei Behrens - "Die Montagstüte" (Bronze) in der Kategorie Regional; ALDI Nord - "Tiefpreis-Aktion mit Spargarantie" (Silber) und Kaufland - Prospekt mit Umleger zur Einführung der Kaufland Card XTRA (Bronze) in der Kategorie Klassik Food; Kölle Zoo - Prospekt März 2026 (Silber) und Blumen Risse - "Blütenlust bei Blumen Risse" (Bronze) in der Kategorie Klassik Non-Food.

Der Deutsche Prospekt Award wurde erstmals 2021 vergeben. Im laufenden Jahr hatten sich 130 Unternehmen um die Würdigung beworben. Sebastian Schaeffer, Geschäftsführer im BDZV für den Bereich Kostenlose Wochenzeitungen, attestiert dem Jahrgang 2026 "ein insgesamt hohes Qualitätsniveau". Die Verlängerung ins Digitale wachse zusehends. "Wir erleben derzeit eher Evolution als Revolution. Viele Unternehmen entwickeln ihre Konzepte konsequent weiter", so Schaeffer. Bemerkenswert sei die hohe Zahl regionaler Einreichungen: "Auch regionale und mittelständische Unternehmen nutzen Prospekte für Kundenbindung, lokale Markenbildung, Information und Aktivierung."

Mitglieder der Fachjury 2026 sind: Dirk Engel, Katja Heintschel von Heinegg, Babak Kharabi, Ralf Richter, Andreas Riekötter, Thomas Sarnowski, Guido Schneider, Stan Skolnik, Haldun Tuncay und Sebastian Schaeffer.

Fotos von der Preisverleihung stehen hier zur Verfügung (Fotocredit: BVDA / Bernd Brundert).

Pressekontakt:

Sebastian Schaeffer

Geschäftsführer im BDZV für den

Bereich Kostenlose Wochenzeitungen

Tel.: 030/726298-2824

Mail: presse@bvda.de

Original-Content von: Bundesverband kostenloser Wochenzeitungen e.V. (BVDA), übermittelt durch news aktuell

Slotozilla Hosts Exclusive Halloween Casino Bonuses for 2026

PHILADELPHIA, Oct. 27, 2026 /PRNewswire/ -- Slotozilla has launched its Halloween 2026 campaign, bringing together a collection of exclusive seasonal casino promotions for players looking for Halloween-themed bonus offers. By bringing a variety of perks together in one place, the brand continues to build its presence in the international affiliate market.

Slotozilla's dedicated Halloween promo pages offer a convenient starting point for discovering exclusive spooky deals and comparing bonus types, terms, and conditions. It's also a gateway for players seeking incentives that aren't available elsewhere or directly from the platform.

A Variety of Seasonal Casino Promotions

The Slotozilla Halloween bonus collection brings together different types of offers, giving users a way to explore promotions suited to their individual interests and eligibility. The available selection may include welcome bonuses, no deposit offers, free spins, deposit deals, and other seasonal rewards.

- Welcome bonuses: Players joining a new casino during this October event may find exclusive, limited-time sign-up rewards, some of which offer greater value than their year-round counterparts.

- No deposit bonuses: For users who'd rather not deposit, several of Slotozilla's partners offer no deposit promotions new users can claim without spending anything.

- Free spins: Consistently popular with Slotozilla's readers, free spins on Halloween-themed games make up a large part of the seasonal collection.

- Deposit bonuses: Aimed at players who have already claimed a welcome offer, deposit bonuses provide extra funds or perks with each account top-up.

- Other seasonal rewards: Slotozilla also offers additional Halloween-themed seasonal rewards, including cashback and mini games. It highlights these wherever they're available.

Halloween Offers Under One Roof

The advantage of Slotozilla's October event bonus lineup is that players can find a Halloween casino bonus that suits their preferences and eligibility without scouring multiple casino pages.

For many gambling platforms, highlighting their perks and getting them in front of players is the hard part. Slotozilla makes this easy with its collated bonus selections.

Country-Specific Halloween Casino Promotions

Slotozilla's Halloween campaign reflects differences across casino markets, where availability, eligibility rules, and operator restrictions vary by country. The platform directs users towards collections relevant to their GEO.

Dedicated Slotozilla Halloween pages cover Australia, Canada, the United Kingdom, New Zealand, Germany, Austria, Poland, Spain, Mexico, Portugal, France, Romania, Finland, Denmark, Sweden, Italy, Hungary, Greece, Bulgaria, the Netherlands and Luxembourg.

This country-focused structure helps users begin their search with promotions intended for their market, rather than displaying offers customers may ultimately be ineligible for. Benefits available in one country may not be available elsewhere, so users should always confirm the applicable conditions on the relevant page.

Responsible Participation

Slotozilla takes its responsibilities to heart, regularly reminding players that seasonal promotions should be approached as entertainment rather than a way to make money. It also notes that bonus funds may come with wagering requirements and other restrictions, and that there is no guarantee of winning or withdrawing money.

Slotozilla: The Big Picture

Slotozilla is an online casino guide that offers gambling reviews, bonus comparisons, and more. With its Halloween 2026 bonus collection, it gives players one place to find exclusive seasonal promotions, compare terms, and find offers available in their country. The event-dedicated pages will remain live throughout October, so players can check back as new seasonal offers are added.

Media Contact:

Slotozilla

[email protected]

Photo(s):

https://www.prlog.org/13178614

SOURCE www.slotozilla.com

Share this article

Gargle's new platform brings essential marketing metrics into one convenient dashboard, helping dentists track performance, measure ROI, and make more informed decisions.

LEHI, Utah, Oct. 27, 2026 /PRNewswire/ -- Gargle, a leading dental-specific digital marketing company, has announced the launch of its new Gargle App, a centralized platform designed to give dental practices greater transparency and control over their marketing performance.

The new app provides Gargle clients with convenient access to key marketing metrics in one place, making it easier to understand how their digital marketing efforts are performing and where opportunities for growth exist.

As dental practices continue to invest in websites, search engine optimization (SEO), paid advertising, social media, and other digital marketing channels, understanding the impact of those investments has become increasingly important.

Gargle's new app is designed to simplify that process.

Bringing Marketing Performance Into Focus

Rather than navigating multiple reporting platforms or relying solely on periodic performance updates, Gargle clients can use the app to access their marketing data through a centralized dashboard.

The platform is designed to help dental practices monitor important performance indicators, including:

- Website Performance: Understand website traffic, engagement, and how prospective patients interact with their online presence.

- Google Ads Performance: Monitor advertising activity and key campaign metrics to better understand paid marketing investments.

- Search Visibility: Track SEO performance and how effectively a practice is reaching prospective patients through online search.

- Call Tracking: Gain insight into incoming calls generated by marketing efforts and opportunities to connect with new patients.

- Marketing ROI: Review performance indicators that help connect marketing activity with measurable business outcomes.

By bringing these insights together, Gargle aims to make marketing reporting more accessible, actionable, and meaningful for dental practice owners.

Moving Beyond Marketing Metrics to Meaningful Results

For many dentists, the challenge isn't simply investing in marketing. It's understanding whether that investment is delivering results.

Website visits, advertising clicks, and search rankings can provide valuable insights, but dental practices also need to understand how those activities contribute to patient interest and practice growth.

"Our new app gives clients a clearer picture of their marketing performance in one convenient place. We want dentists to spend less time trying to interpret complicated reports and more time focusing on what matters most: growing their practices and caring for their patients" said Josh Lowe, VP of Product at Gargle.

The app also supports Gargle's broader approach to dental marketing, which emphasizes measurable performance, ongoing optimization, and strategies tailored to the unique needs of dental practices.

A Continued Investment in Dental Marketing Innovation

The launch of the Gargle App represents another step in the company's ongoing investment in technology and marketing innovation.

As the digital landscape evolves with AI-powered search, changing patient behaviors, and increasingly competitive online advertising, Gargle continues to develop solutions that help dental practices stay informed and competitive.

By combining dental-specific marketing expertise with accessible performance reporting, Gargle is working to make sophisticated digital marketing strategies easier for dentists to understand and evaluate.

"Our goal is simple: take the guesswork out of dental marketing," added Josh. "The Gargle App gives our clients greater visibility into the work we're doing and the results we're working toward. It's another way we're helping dental practices make smarter, data-driven decisions."

The Gargle App is being introduced as part of Gargle's ongoing commitment to improving the client experience and providing dental practices with the tools and insights they need to support long-term growth.

About Gargle

Gargle is a full-service digital marketing company dedicated exclusively to the dental industry. Trusted by hundreds of dentists, Gargle provides website design and development, search engine optimization (SEO), AI search optimization (AEO/GEO), Google Ads, social media marketing, online reputation management, and more.

With a focus on transparency, measurable results, and dental-specific expertise, Gargle helps practices strengthen their online presence, attract prospective patients, and make more informed marketing investments.

To learn more, visit www.gargle.com.

SOURCE Gargle Inc.

Share this article

TROY, Ala., Oct. 27, 2026 /PRNewswire/ -- Lockheed Martin (NYSE: LMT) has been awarded a $694M contract from the U.S. Air Force for production of the Air-Launched Rapid Response Weapon (ARRW). The new capability brings sustained and maneuverable hypersonic capabilities to America's Arsenal of Freedom and is the culmination of years of developmental and test partnership between Lockheed Martin and the U.S. Air Force.

THE BIG PICTURE

Integrated on the B-52, ARRW brings hypersonic strike capability that can be rapidly deployed to the U.S. Air Force. Its production readiness makes it an essential asset for the military, providing a critical capability to counter emerging threats.

Earlier today, Lockheed Martin broke ground on an expansion of Building P-20 in Troy, Alabama, that will add 47,000 square feet of production space for ARRW. The expansion will triple the current facility's production space and generate new American jobs over the next four years, adding to the almost 4,000 Lockheed Martin employees in the state of Alabama. The world-class facility will prepare the workforce to build ARRW using advanced manufacturing, robotics and digital technologies.

WHY IT MATTERS

- ARRW will travel at speeds greater than Mach 5, more than five times the speed of sound, to rapidly engage targets from significant standoff ranges.

- ARRW is designed to operate in extreme environments through the use of advanced materials to manage extreme heat, an advanced technology package to maintain accuracy and lethality, and capability to overcome a wide range of defenses.

- Lockheed Martin has already funded efforts, materials, and equipment required to start ARRW's production, underscoring the company's commitment to delivering this critical capability to the U.S. Air Force at speed and scale.

EXPERT PERSPECTIVE

"The ARRW production contract award showcases Lockheed Martin's ability to develop and begin production on cutting-edge systems at unprecedented speed and scale," said Tim Cahill, president, Lockheed Martin Missiles and Fire Control. "ARRW expands our weapon systems portfolio and launches a critical, high-precision, and sustained hypersonic capability that will enhance the U.S. Air Force's strategic advantage across multiple domains."

ADDITIONAL CONTEXT

- Lockheed Martin's $8-9 billion investment through 2030 to meet munitions demand is already delivering tangible results, including our $67 million investment for ARRW production facility expansion and equipment, prior to receiving government funding.

- The company also continued research and development, ensuring long-term support and rapid delivery of the U.S. Air Force's need for an air-launched hypersonic strike capability.

- Lockheed Martin is the leader in hypersonic strike capabilities, leveraging more than 60 years of hypersonic strike experience to deliver game-changing capabilities in support of the U.S. National Defense Strategy and security objectives of allied nations.

About Lockheed Martin

Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com.

SOURCE Lockheed Martin

Share this article

Colonel (Ret.) Mark "SNapper" Mattison Shares Lessons Learned from the Air Force's Initial Pilot Training Program and Lays Out a Path to Transform Training Across All Services

SAN ANTONIO, Oct. 27, 2026 /PRNewswire/ -- More than 300 senior military leaders, program managers, instructors, and aviation industry executives gathered in San Antonio for the 2026 IDGA Military Flight Training USA Summit. The summit is one of the premier forums for discussing how we modernize military flight training. It puts uniformed and civilian leaders in the same room to trade ideas, test new training methods, and find better ways to produce the next generation of military aviators.

Among the featured industry speakers was Colonel (Ret.) Mark "SNapper" Mattison, Vice President of Military Programs for US Aviation. Mattison addressed an audience drawn from every branch of the U.S. Armed Forces. Drawing on decades in military aviation and his role leading US Aviation's Initial Pilot Training (IPT) program, he took on one of the toughest problems facing the services today: how to modernize training, increase capacity, cut costs, and get uniformed personnel out of training units and back into operational warfighting assignments.

It was the right audience for that conversation. Flag officers and senior decision makers from Air Education and Training Command (AETC), Chief of Naval Air Training (CNATRA), and the Army Aviation Center of Excellence were in the room. These commands build the people, capabilities, and training systems that keep American military aviation on top, and they brought hard-earned operational perspective to the discussion.

Mattison didn't come to talk theory. He came to share what US Aviation has actually done.

A Transformational Approach to Initial Pilot Training

In December 2025, the United States Air Force awarded US Aviation a ten-year, $835 million contract to administer the Air Force's Initial Pilot Training program. US Aviation is the sole contracted IPT provider, a significant shift in how the Air Force prepares future pilots for advanced training.

Mattison explained that IPT represents a real change to the traditional model. For decades, the services have run initial aviation training on their own installations, with their own aircraft, instructors, maintainers, and support personnel. That model has worked, but it consumes a large amount of military manpower and resources to operate and sustain.

IPT takes a different approach. It puts capability that already exists in the civilian aviation industry to work for the Air Force.

Civilian training organizations already have the infrastructure, the experienced instructors, the maintenance capability, and the federally recognized certifications in place. By using them, the Air Force can give students a solid foundation in flying without rebuilding every piece of the training enterprise on its own.

Mattison noted that US Aviation's experience standing up and running IPT offers useful lessons for any military organization weighing a similar approach.

The goal, he said, is not simply to outsource training. It is to take a hard look at how the military spends its limited resources while holding the line on the quality, discipline, and performance standards expected of military aviators.

Three Principles for Modernizing Military Training

Mattison built his presentation around three principles that offer a framework for transforming training across the Armed Forces.

First, leverage existing civilian training capacity. The United States has a large, mature civilian flight training industry, with established facilities, aircraft fleets, experienced instructors, maintenance personnel, and proven training management systems. Rather than spend military dollars duplicating that capability, the services can use infrastructure and expertise that is already performing in the private sector.

Second, capitalize on civilian certifications and qualifications. Civilian flight training operates under standards and oversight set by the Federal Aviation Administration (FAA). Building recognized civilian certifications into military training gives the services an established system of standards, checkrides, inspections, and qualifications. That reduces duplicative government oversight while keeping performance requirements clearly defined.

Mattison pointed out that FAA oversight is a built-in advantage. The FAA is already an independent regulator responsible for evaluating civilian training organizations. That frees the services to focus their oversight on military-specific requirements and contract performance instead of recreating a civilian certification and inspection system from scratch.

Third, redirect military manpower into operational warfighting units. This may be the most strategically important benefit: returning personnel now assigned to institutional training organizations to operational units.

Every instructor, maintainer, administrator, or support specialist whose training duties can responsibly move to a civilian partner is manpower that can be reinvested in operational readiness. For leaders facing persistent personnel shortages and growing operational demands, the payoff goes well beyond dollars saved.

It also puts each side where it adds the most value. A civilian partner like US Aviation can focus on what it does best, building sound foundational flying skills, while our warfighters pass on the combat experience and tactical expertise that only they can provide and that no civilian organization can replace.

Lessons Learned: "It's Hard"

One of the most memorable moments came during the Q&A, when a former three-star Air Force general officer asked what US Aviation had learned in its first two years of building the IPT program.

Mattison didn't hesitate.

"It's hard."

The answer drew laughter across the room, but Mattison quickly explained just how complex a high-volume flight training operation is.

"Graduating one class of 25 students earning three certificates in 139 days is challenging," he said. "Two classes overlapping at the same time isn't twice as hard, it's three times as hard."

Then he described what happens when a third class starts before the first two have graduated.

With three classes in the pipeline, coordinating aircraft availability, instructor schedules, maintenance, student progression, checkrides, and training resources gets dramatically harder.

"The difficulty rises exponentially when the third class is added to the mix," Mattison said.

His point drew a sharp line between running a typical civilian flight school and running a large-scale military training program with tight timelines, defined graduation requirements, and multiple classes moving at once.

Flight training is resource-intensive by nature. Aircraft have to be available and maintained, instructors have to be qualified, students have to complete prescribed training events, and weather or maintenance problems can throw off the schedule for classes behind them.

The more classes overlap, the more those variables interact. One delayed flight lesson in one class can affect aircraft and instructor availability in another, and the pressure cascades through the whole operation.

The takeaway: success takes more than airplanes and instructors. It takes disciplined program management, tight scheduling, careful resource allocation, and the flexibility to adjust fast when things don't go to plan.

An Opportunity Beyond Air Force Pilot Training

While US Aviation's experience centers on Air Force IPT, Mattison encouraged attendees to think about how the same approach could apply to other training disciplines and other services.

The underlying principle is simple: the military should concentrate its people and unique capabilities on missions that require military expertise and look to civilian partners for training functions that can be done well outside the uniformed force.

Public-private partnerships with civilian schools like US Aviation act as a force multiplier. Civilian partners bring the resources and infrastructure to deliver basic skills at scale, which lets the Armed Forces put their time and talent into honing the warfighting expertise that only they can develop.

The presentation drew questions about US Aviation's capabilities, the challenges of implementing IPT, and the potential to replicate the model across other services and training programs.

Those conversations reinforced how important it is for military leadership and civilian industry to work together as the services look for ways to modernize training without lowering the bar.

Returning Military Manpower to the Fight

US Aviation's Initial Pilot Training program offers a potential blueprint for broader transformation of military training across the Armed Forces.

For the leaders gathered in San Antonio, Mattison's message was clear: the future of military training doesn't have to mean more facilities, more equipment, or more uniformed personnel assigned to institutional training.

It may mean changing how the Armed Forces use America's civilian training industry.

By leveraging civilian capacity, capitalizing on federally recognized certifications, and returning military manpower to operational units, the Armed Forces can train more efficiently, reduce costs, and strengthen the warfighting force while keeping the rigorous standards America's military professionals are known for.

SOURCE US Aviation Academy

Share this article

WASHINGTON and SAN FRANCISCO and MIAMI, Oct. 27, 2026 /PRNewswire/ -- Martis Capital, a private equity firm exclusively focused on the middle market healthcare sector, has been named to Inc.'s 2026 Founder-Friendly Investors list, which recognizes the private equity firms, venture capital firms, and lenders with a demonstrated record of backing founder-led companies. Of the 294 firms recognized this year, Martis earned the honor for the sixth consecutive year and was one of 14 healthcare-exclusive private equity firms.

The prestigious Founder-Friendly Investors list celebrates the investors and firms that work closely with entrepreneurs and remain engaged with the businesses they back. Honorees are recognized for their approach to partnering with founders and supporting their companies through growth and beyond.

"Founders don't get to choose their investors twice, so it means a great deal when the people who've actually worked with us say we were the right choice," said Mario Moreno, Managing Partner of Martis Capital. "Healthcare is a demanding place to build a company. The regulatory, clinical, and operational complexity is real, and founders need a partner who understands it and shows up when it matters. That's the role we've tried to play since 2011, and earning this recognition for six years running reflects the relationships we've built with our founders."

"When we partnered with Martis, we were looking for more than capital. We wanted a team that respected the foundation of what we'd built and were eager to help accelerate our growth," said Frank Burrell, CEO of Deerfield Group, a marketing and communications firm for the healthcare and life sciences sectors and a portfolio company of funds advised by Martis. "Martis earned Inc.'s Founder-Friendly recognition through its consistent commitment to the businesses it backs. For Deerfield, this means supporting our vision, providing meaningful strategic guidance, making key connections, and trusting our leadership. As specialists in healthcare investing, Martis deeply understands our industry, and together we are building what's next for healthcare marketing, media, and communications."

To compile the Founder-Friendly Investors list, Inc. went straight to the source: entrepreneurs who have sold to private equity and venture capital firms. Founders completed questionnaires about their experiences partnering with private equity, venture capital, and debt firms and shared data on how their companies have performed during these partnerships. The resulting list highlights investors that founders identified as strong partners throughout the investment process.

For more information or to view the complete list of honorees, visit https://www.inc.com/founder-friendly-investors.

About Martis Capital

Based in Washington, DC, San Francisco, and Miami, Martis Capital is a founder-friendly capital partner for growth-oriented healthcare companies. Since 2011, Martis Capital has raised more than $2.2 billion from a global base of institutional clients to invest in the middle-market North American healthcare sector. More information is available at www.martiscapital.com.

About Inc.

Inc. is the leading media brand and playbook for entrepreneurs and business leaders. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.

Disclosures

Inc. granted Martis Capital the 2026 Founder-Friendly Investors recognition on August 13, 2026, based on an evaluation covering the preceding 12-month period. Martis Capital did not exercise any influence or control over the criteria used or the results generated by Inc. This recognition should not be construed as an endorsement or recommendation of Martis Capital by Inc., the ranking entity, or any regulatory authority. Martis Capital paid a fee to be considered for this award and in connection with the use and distribution of this recognition.

Frank Burrell is CEO of Deerfield Group, a portfolio company of funds advised by Martis Capital. He is not a client of Martis Capital or an investor in any fund advised by Martis Capital and received no compensation for his statement. His comments reflect his experience working with Martis Capital and may not be representative of the experiences of other portfolio companies, clients, or investors.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Past performance is not indicative of future results.

Media Contact

Margaret Kirch Cohen

Newton Park PR

+1 847-507-2229

[email protected]

SOURCE Martis Capital

Share this article

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness

New Long-Term UPLIZNA Data in IgG4-Related Disease and Real-World Evidence for KRYSTEXXA and TAVNEOS Further Highlight Amgen's Broad Portfolio and Commitment to People Living with Rare Diseases

THOUSAND OAKS, Calif., Oct. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to present new data across its portfolio, including in rare and other serious autoimmune diseases at the American College of Rheumatology (ACR) Convergence 2026.

Key presentations include:

Dazodalibep Significantly Reduces Systemic Disease Activity in Patients with Sjögren's Disease and Moderate-to-Severe Disease Activity: Results from the Phase 3 OASIZ-301 Trial

Late-Breaking Abstract #22, Wednesday, November 11, from 8:45â9:00 a.m. ET

Sjögren's disease is a systemic autoimmune disease that can affect the entire body. Along with symptoms of extensive dryness, other serious manifestations may include profound fatigue, chronic pain, major organ involvement, neuropathy, and an increased risk of lymphoma. There are currently no FDA-approved medicines for Sjögren's disease.

Amgen will present late-breaking results from the Phase 3 OASIZ-301 study evaluating dazodalibep in adults living with Sjögren's disease and moderate-to-severe systemic disease activity. Dazodalibep is a CD40L antagonist that disrupts interactions between T cells, glandular epithelial cells, B cells and other antigen-presenting cells.

Patients entered the OASIZ-301 study with an average European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) score of 10.2. Results show that at Week 48 both dazodalibep dosing regimens (1,500 mg every four weeks and 3,000 mg every 12 weeks) demonstrated statistically significant and clinically meaningful reductions in systemic disease activity compared with placebo. Treatment effects were observed as early as four weeks. Disease activity scores improved by a least-squares mean change from baseline of -5.6 points in patients receiving dazodalibep every four weeks (difference vs placebo, â1.8; adjusted p0.001) and -5.2 points in those receiving treatment every 12 weeks (difference vs placebo, â1.4; adjusted p=0.010), compared with -3.8 points for placebo.

Additionally, dazodalibep every four weeks also demonstrated statistically significant and clinically meaningful improvements in the key secondary endpoint of patient-reported dryness compared with placebo. Patients reported greater reductions in dryness, as measured by both the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) dryness score (least-squares mean change from baseline, â2.50 vs. â1.33 for placebo; adjusted p0.001) and the Diary for Assessing Sjögren's Patient Reported Index (DASPRI) dryness score (least-squares mean change from baseline, â1.98 vs. â1.05 for placebo; adjusted p0.001). Treatment emergent adverse events (TEAEs), serious adverse events and TEAEs leading to discontinuation were observed at similar rates across treatment groups.

"For patients living with Sjögren's disease, systemic disease activity and symptoms can have a significant impact on their health and daily lives, yet treatment options remain limited," said Dr. Teresa K. Tarrant, MD, Associate Professor of Medicine, Duke University. "The rapid improvements in ESSDAI, as well as self-reported dryness, observed with dazodalibep are particularly encouraging. These findings represent meaningful progress in our understanding of how we may be able to better manage both the systemic and symptomatic manifestations of this complex disease."

Beyond dazodalibep, Amgen's scientific program at ACR Convergence 2026 will also include data from Phase 3 MITIGATE open-label extension describing the long-term safety profile and sustained efficacy of UPLIZNA in IgG4-RD. The company will also present real-world evidence from KRYSTEXXA® and TAVNEOS® in uncontrolled gout and ANCA-associated vasculitis, respectively.

"The data we're presenting at ACR demonstrate the breadth of Amgen's portfolio and pipeline across rare and other serious autoimmune diseases," said Paul Burton, M.D., Ph.D., senior vice president and chief medical officer at Amgen. "By advancing investigational therapies, generating long-term clinical evidence and building on our understanding of medicines in real-world settings, we're working to address significant unmet needs for patients living with some of the most complex and serious diseases."

Additional Amgen-sponsored abstracts:

UPLIZNA® (inebilizumab-cdon)

- Efficacy and Safety of Inebilizumab for the Treatment of IgG4-RD Across Age Subgroups: Analysis from the Open-label Period of the MITIGATE Trial

Abstract #2107; Poster Session C; Tuesday, November 10, 2026, 10:30 a.m.â12:30 p.m. ET

- Efficacy and Safety of Inebilizumab in Newly Diagnosed and Recurrent IgG4-RD Patients: Results From the Open-Label Period of the MITIGATE Study

Abstract #1129; Poster Session B; Monday, November 9, 2026, 10:30 a.m. â12:30 p.m. ET

- Long-Term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from the Year 1 Open-Label Period of a Phase 3 Trial (Encore)

Abstract #0177; Poster Session A; Sunday, November 8, 2026, 10:30 a.m. â12:30 p.m. ET

TAVNEOS® (avacopan)

- Effectiveness and Safety of Avacopan Added to Standard of Care (SOC) Versus SOC Alone in ANCA-associated Vasculitis

Abstract #2133; Poster Session C; Tuesday, November 10, 2026, 10:30 a.m.â12:30 p.m. ET

- Glucocorticoid-Associated Conditions in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis With Prolonged Moderate-to-High Dose Glucocorticoid Use (Encore)

Abstract #1156; Poster Session B; Monday, November 9, 2026, 10:30 a.m. â12:30 p.m. ET

KRYSTEXXA® (pegloticase)

- Induction and Maintenance of Gout Remission During Intensive Urate-Lowering with Pegloticase: Post Hoc Analysis of a 2.5 Year Open-Label Extension Study

Abstract #0714; Poster Session A; Sunday, November 8, 2026, 10:30 a.m.â12:30 p.m. ET

- Real-World Attainment and Durability of Gout Remission Following Pegloticase Initiation in a U.S. Practice Based Rheumatology Network

Abstract #0853; Poster Session A; Sunday, November 8, 2026, 10:30 a.m.â12:30 p.m. ET

- Induction of Clinical Remission in Patients with Uncontrolled Gout Treated with Pegloticase and Immunomodulation: Experience in Two Community Rheumatology Practices

Abstract #2648; Poster Session C; Tuesday, November 10, 2026, 10:30 a.m.â12:30 p.m. ET

- The Pattern and Severity of Gout Flares Prior to and During Pegloticase Treatment in the MIRROR and AGILE Clinical Trials

Abstract #2657; Poster Session C; Tuesday, November 10, 2026, 10:30 a.m.â12:30 p.m. ET

- Real-World Use of Immunomodulation Co-therapy Among Pegloticase New Users

Abstract #2653; Poster Session C; Tuesday, November 10, 2026, 10:30 a.m.â12:30 p.m. ET

About Dazodalibep

Dazodalibep is a potential first-in-class CD40L antagonist fusion protein that is designed to target immune activation by disrupting interactions between T cells, glandular epithelial cells, B cells and other antigen-presenting cells. Dazodalibep is being studied in two Sjögren's disease patient groups: those with moderate-to-severe systemic disease and those with high symptom burden and low systemic disease who suffer from dryness, fatigue, and/or pain that profoundly impact daily life.

About OASIZ 301 and the Dazodalibep Development Program

OASIZ 301 is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in patients with Sjögren's disease with moderate-to-severe systemic disease activity (ESSDAI ⥠5) (n=approximately 621). The primary endpoint of the study is change from baseline in ESSDAI score at Week 48.

Key secondary endpoints evaluated dryness, tender and swollen joints, fatigue, and ESSDAI[5] response, defined as a decrease of at least 5 points from baseline.

Additionally, Amgen is conducting OASIZ 303, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of dazodalibep in patients with high symptom burden with low systemic Sjögren's disease activity. The OASIZ 303 study is expected to complete in Q4 2026.

Amgen is also conducting OASIZ 304, an open-label, long-term extension study evaluating the long-term safety and tolerability of dazodalibep in eligible participants from OASIZ 301 and OASIZ 303.

About Sjögren's Disease

Sjögren's disease (SjD) is a heterogeneous autoimmune disease, where patients can experience persistent dryness, fatigue, and pain, often alongside systemic involvement that can be progressive. Although SjD is the second most common autoimmune rheumatic disease, it remains widely underrecognized, with the full extent of its systemic severity and debilitating symptomatic impact on patients' lives often underestimated. Despite this burden, there are currently no approved therapies for SjD, and many patients continue to experience persistent systemic disease activity and debilitating symptoms.

About UPLIZNA® (inebilizumab-cdon)

UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease process (autoantibody-producing CD19+ B cells, including plasmablasts and some plasma cells). The precise mechanism by which UPLIZNA exerts its therapeutic effects in IgG4-RD is unknown. After two initial infusions, patients need one dose of UPLIZNA every six months.

About TAVNEOS® (avacopan)

TAVNEOS is an orally administered small molecule indicated as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis (GPA/MPA). It is a selective complement 5a receptor (C5aR) antagonist that targets inflammation by blocking the activity of C5a, a key driver of neutrophil activation.

Cash dividend payable in the fourth quarter of 2026

CAMDEN, N.J., Oct. 27, 2026 /PRNewswire/ -- American Water Works Company, Inc. (NYSE: AWK) announced that its board of directors today declared a quarterly cash dividend payment of $0.8950 per share of common stock, payable on December 1, 2026, to all shareholders of record as of November 12, 2026.

This quarterly dividend is a continuation of the annualized dividend approved by the Board and announced on April 29, 2026.

American Water offers a dividend reinvestment and direct stock purchase plan called American Water Stock Direct (the "Plan"), which enables shareholders to reinvest cash dividends and purchase additional shares of American Water common stock without any brokerage commissions or service charges. Shareholders and other persons may obtain a copy of the Plan prospectus and an enrollment form by contacting Equiniti Trust Company, LLC at 888-556-0423, visiting Equiniti's website at equiniti.com/us, contacting American Water's Investor Relations department at 856-566-4005 or by visiting the Investor Relations webpage located at ir.amwater.com/resources.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. The offer is being made solely through the Plan prospectus.

About American Water

American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886 and celebrating 140 years in 2026, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to approximately 14 million people with regulated operations in 14 states and on 19 military installations. American Water's approximately 7,000 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.

AWK-IR

SOURCE American Water

Share this article

Federal Signal Corporation Declares Dividend of $0.15 per share

DOWNERS GROVE, Ill., Oct. 27, 2026 /PRNewswire/ -- Federal Signal Corporation (NYSE:FSS) today announced that its Board of Directors declared a quarterly cash dividend of fifteen cents ($0.15) per share on its common stock. The dividend is payable on December 1, 2026 to stockholders of record at the close of business on November 13, 2026.

About Federal Signal

Federal Signal Corporation (NYSE: FSS) builds and delivers equipment of unmatched quality that moves material, cleans infrastructure, and protects the communities where we work and live. Founded in 1901, Federal Signal is a leading global designer, manufacturer and supplier of products and total solutions that serve municipal, governmental, industrial and commercial customers. Headquartered in Downers Grove, Ill., with manufacturing facilities worldwide, the Company operates two groups: Environmental Solutions and Safety and Security Systems. For more information on Federal Signal, visit: https://www.federalsignal.com.

SOURCE Federal Signal Corporation

Share this article

EdgeStart is a self-contained, 8-GPU NVIDIA cabinet that enables building owners to earn money from their available solar power and batteries.

NEW YORK, Oct. 27, 2026 /PRNewswire/ -- Lektra, Inc., a distributed energy and artificial intelligence company, today began taking orders for EdgeStart, a self-contained server cabinet that commercial and industrial building owners, solar and storage sites, and energy developers to house in underutilized facility space and power with existing solar arrays and batteries. Lektra installs the system, operates it remotely, sells its computing capacity to AI customers for inference and other GPU workloads through Lektra Cloud, and pays the owner 80 percent of the revenue.

Many buildings with solar panels make more power than they use. In some markets, utility tariffs and interconnection rules mean exported solar earns only a few cents per kilowatt-hour. Using a patented process, EdgeStart provides a better way for owners to more efficiently generate additional income. Each cabinet holds an 8-GPU NVIDIA server (the same class of hardware AI companies rent from the largest clouds), an online UPS, a metered power distribution unit, a firewall, and a switch. A live dashboard shows usage, energy, and earnings, and Lektra handles customers, billing, monitoring, and support. An owner can start with one cabinet and expand as the need arises.

"EdgeStart is the first building block in our vision to create a more resilient and impactful computing network where power is readily available, whether solar, batteries, or microgrids," said Karl Andersen, Founder and Chief Executive Officer of Lektra. "AI infrastructure doesn't have to be concentrated behind the walls of a massive data center. Businesses across the country have energy, available space, and the ability to support computing, and EdgeStart connects them into a coordinated network that pays them to power AI compute."

Large, centralized data centers can take years to develop because they require substantial construction, permitting, land acquisition, utility coordination, and access to a significant amount of reliable power. Additionally, political and community negotiations often present hurdles where projects raise concerns about electricity rates, water use, land use, and grid capacity. EdgeStart provides a flexible and opportunistic way to put computing in buildings that can easily support it, or already have it.

EdgeStart is the entry point to Lektra's EdgeScale data center product suite, along with Edge Pro and Edge Max. Edge Pro serves larger commercial deployments, and Edge Max supports multi-megawatt installations. Lektra's EdgeScale data centers, which operate at 20 MW or less, are deployed at eight sites today.

Lektra is launching two models. The EdgeStart RTX has eight NVIDIA RTX PRO 6000 Blackwell GPUs, costs $310,197, and draws about 7 kW at peak. Lektra estimates owner earnings of about $9,700 a month in the first year. The EdgeStart B300 has eight NVIDIA B300 GPUs, costs $840,951, and draws about 14.5 kW at peak, with estimated owner earnings of about $36,950 a month. Prices cover the installed hardware and shipping.

Owners can pay cash or finance through Blue Street Capital at 9 percent over 48 months with 20 percent down, subject to credit approval. Estimated monthly payments are about $6,200 for the RTX and about $16,700 for the B300.

The earnings estimates assume 730 contracted hours a month at current market rates, the 80 percent owner share, power at $0.10 per kilowatt-hour, and the cost of fiber and data storage.

"Uber created a shared economy for transportation, and Airbnb did the same for real estate. Yet energy, one of the world's most important resources, has remained largely outside that transformation," continued Andersen, Founder and Chief Executive Officer of Lektra. "EdgeStart is the first step toward a shared economy where the owners of energy infrastructure can reasonably and mindfully become active participants in the AI economy, rather than electrical grid customers."

Lektra calls the building owners who run EdgeStart energy hosts. A host starts with a site assessment on lektra.com, followed by an engineering review and an earnings model. The host then buys the system, with cash or financing, and then Lektra installs, tests, and brings it online.

EdgeStart is available to order now at lektra.com. Buyers can also request a site assessment or contact [email protected].

EdgeStart is being introduced as part of Lektra's expanding portfolio of distributed AI infrastructure solutions. Initial configurations will support select NVIDIA GPU architectures, with additional hardware options and deployment configurations planned.

Lektra

Lektra, Inc. is a distributed energy and artificial intelligence infrastructure company developing a network of computing resources powered by distributed energy. By integrating GPU computing, energy management technology, and cloud orchestration, Lektra enables businesses and energy owners to participate in the AI infrastructure economy. Its EdgeStart, Edge Pro, and Edge Max solutions are designed to support scalable deployments across commercial, industrial, and distributed energy environments.

Forward-Looking Statements

This release contains forward-looking statements concerning product development, commercial availability, market opportunities, anticipated performance, and potential revenue generation. Actual results may differ materially due to market demand, GPU utilization, electricity costs, equipment availability, operating expenses, and other factors. Illustrative computing revenue figures do not constitute guaranteed earnings or investment returns.

SOURCE Lektra, Inc.

Share this article